This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The most studied ring destructive pathway is the Kodama pathway and it was initially identified in Pseudomonas abikonensis and Pseudomonas jijani. The pathway comprises four main steps: i) the successive hydroxylation by NADH-dependent dioxygenases of the carbons in one of the aromatic rings, followed by ii) the dehydrogenation of the ring by a NAD+ cofactor and further iii) oxygenation promoting ring cleavage and formation of a pyruvyl branch; concluding with iv) the hydrolysis of the pyruvyl substituent to release pyruvate and the remaining of the substrate. Since the end products of the pathway are still water soluble sulfur compounds, the pathway has often been disregarded as an appealing pathway for industrial applications, in particular by the oil industry. The most well-studied sulfur specific pathway is the 4S pathway, first discovered in the bacterium Rhodococcus erythropolis (strain IGTS8), which was observed to remove sulfur from dibenzothiophenes and derivatives in three steps: i) a double oxidation of the sulfur (to sulfoxide and sulfone) performed by a flavin-dependent monoxygenase, followed by ii) a carbon-sulfur bond cleavage by a second flavin-dependent monoxygenase and a iii) desulfination reaction through which 2-hydroxybiphenyl and sulfite are produced.
Based on this data, alogliptin was chosen for preclinical evaluation. In January 2007 alogliptin was undergoing the phase III clinical trial and in October 2008 it was being reviewed by the U.S. Food and Drug Administration.
== Horticultural uses == The international registration authority for the genus is the American Violet Society, where growers register new Viola cultivars. A coding system is used for cultivar description of ten horticultural divisions, such as Violet (Vt) and Violetta (Vtta). Examples include Viola 'Little David' (Vtta) and Viola 'Königin Charlotte' (Vt). In this system violets (Vt) are defined as "stoloniferous perennials with small, highly fragrant, self-coloured purple, blue or white flowers in late winter and early spring".
When she got to the emergency room, her facial paralysis was coming in and out, because of this she was placed into the stroke ward for observation and a CAT scan and MRI was ordered that resulted negative. A neurologist came in and told her it was all just a psychosomatic response to stress and nothing more. A big reason she does not trust doctors is for the fact that she is a woman of color, and she feels she's not heard by the generic privileged doctor complex. When reaching out to Dr. Lisa Sanders, both Joe and Ann had already been tested and ruled out for dozens of diseases such as Multiple Sclerosis, Parkinson's, and Lupus. Joe specifically has two very serious illnesses, the first one being his unexplained paralysis and the second being an incurable form of blood cancer he was diagnosed with 15 years back. Joe thought he only had a few years to live, but he was placed on a clinical trial that has kept him alive until this day. Dr. Lisa Sanders now wants to know if his blood cancer has anything to do with his paralysis, especially now that he has movement in his toes. Dr. Lisa Sanders published both Joe and Ann’s stories on different columns to gain different traction from the audience and to not create confusion. The first column published was for Joe’s symptoms and this generated hundreds of responses. The two most reasonable possibilities are CIDP, Chronic Inflammatory Polyneuropathy, aka Guillain-Barre syndrome or the paralysis is a side effect of the clinical drug, Ibrutinib, he is taking to control his blood cancer.
The new 37th district is based in all but the westernmost parts of Austin, with virtually all of the precincts of the exclusively Travis County-based district favoring Democrats to varying degrees; the new district has a White plurality with a 34% Hispanic voting age population. The incumbent is Democrat Lloyd Doggett, who was re-elected with 75.9% of the vote in 2024. On August 21, 2025, Doggett announced that he would not seek re-election due to mid-decade redistricting, and fellow Democratic Rep. Greg Casar being moved into the 37th district. On August 25, 2025, Casar announced his bid for re-election from this district. Kamala Harris won 76.8% of the vote in the new 37th District, which also gave 79.2% of the vote to Colin Allred; in both cases, the highest of any district amongst the state's new congressional districts.
Sources: en.wikipedia.org
Cryptogenic organizing pneumonia (COP), formerly known as bronchiolitis obliterans organizing pneumonia (BOOP), is an inflammation of the bronchioles (bronchiolitis) and surrounding tissue in the lungs. It is a form of idiopathic interstitial pneumonia. It is often a complication of an existing chronic inflammatory disease such as rheumatoid arthritis, dermatomyositis, or it can be a side effect of certain medications such as amiodarone. COP was first described by Gary Epler in 1985. The clinical features and radiological imaging resemble infectious pneumonia. However, diagnosis is suspected after there is no response to multiple antibiotics, and blood and sputum cultures are negative for organisms.
== Other major examples == The cytochrome P450 isozymes play important roles in metabolism and steroidogenesis. The multiple forms of phosphodiesterase also play major roles in various biological processes. Although more than one form of these enzymes have been found in individual cells, these isoforms of the enzyme are unequally distributed in the various cells of an organism. From the clinical standpoint they have been found to be selectively activated and inhibited, an observation which has led to their use in therapy.
Despite this legal authorization, many cross-border dairy processors supplying both the UK and EU markets have phased out the additive to maintain single, unified manufacturing lines. To maintain the bright profile desired by consumers without using E171, European manufacturers increasingly utilize alternative whitening agents. The most common substitute is calcium carbonate (E170), which is added to food dressings to achieve opacity without the use of unregulated nanoparticles.
In 1957, Marvin Margoshes and Bert L. Vallee at Harvard Medical School discovered that in horse kidney cortex, cadmium and zinc levels appeared to be maintained by binding to another molecule which they identified as a protein. They reported in the Journal of the American Chemical Society, concluding:The low sedimentation constant and high metal content of this material are indicative of a low molecular weight protein, probably containing a small number of cadmium atoms per molecule. Characterization of this unusual natural product is in progress.In 1958, Vallee presented the discovery at the International Congress of Biochemistry held in Vienna, and suggested that cadmium must be a natural biomolecule using the unknown protein. He pursued the research with his student Jeremias H. R. Kägi and was able to identify the new protein in 1960. The conclusion in The Journal of Biological Chemistry runs:The present study reports the isolation and characterization of a protein from equine renal cortex which contains 2.9% of cadmium, 0.6% of zinc, and 4.1% of sulfur per g dry weight of protein. This protein has been termed metallothionein in view of its metal and sulfur content.Vallee and Kägi reported further confirmation in the same journal in 1961. They later realised that metallothionein was not a single type of protein. With their collaborators, they could differentiate another related protein but with different amino acid properties and gave the name "metallothionein-1B" in 1970.
The Rhodesian military was backed by the British South Africa Police (BSAP), a well-equipped police force whose title was derived from the law enforcement division of the British South Africa Company. The BSAP had numerous paramilitary units that functioned as auxiliaries to the army. Domestic and external intelligence gathering were vested in the Central Intelligence Organisation (CIO). As a result of the escalating rural insurgency, the Rhodesian Security Forces began to depend more heavily on white conscripts and reservists, the latter of whom were enrolled in a reserve component known as the Territorial Force. The regular elements of the security forces included a disproportionate number of personnel who had seen action during the First Malayan Emergency as well as the Aden Emergency, and their experience gave Rhodesia's defence establishment a solid grounding in counter-insurgency warfare and small unit tactics in particular. Nevertheless, the vastness of the operational area and Rhodesia's limited manpower pool left the army, air force, and BSAP constantly overstretched. Budgetary and resource restraints, coupled with manpower shortages, meant the security forces could not expand quickly enough to match the guerrilla movements, and were almost always outnumbered. Rhodesian units attempted to compensate for their disadvantage in this regard by pursuing an aggressive preemptive and counterstrike strategy, raiding neighbouring states to destroy guerrilla forces in their external sanctuaries.
Sources: en.wikipedia.org
Hence, the perception is that both disseminated HS and MH follow a rapid clinical progression despite therapeutic intervention. This is certainly true once clinical signs are apparent, but the subclinical period is of unknown duration. The HS complex of diseases is best recognized in the Bernese Mountain Dog in which a familial association is apparent. Other breeds are predisposed to HS complex diseases and include Rottweilers, Golden Retrievers, and Flat-coated Retrievers. Although HS complex is not limited to just these breeds and can occur sporadically in any breed. Primary lesions of HS occur in spleen, lymph node, lung, bone marrow, skin and subcutis especially of extremities. Secondary sites are widespread, but consistently include liver and lung (with splenic primary), and hilar lymph node (with lung primary). Clinical signs include anorexia, weight loss, and lethargy. Other signs depend on the organs involved and are a consequence of destructive mass formation. Accordingly, pulmonary symptoms such as cough and dyspnea have been seen. CNS involvement (primary or secondary) can lead to seizures, incoordination and paralysis. Regenerative and non-regenerative anemia have been consistently documented in hemophagocytic HS. Lameness is often observed in periarticular HS. Treatment of HS complex Localized HS affecting skin and subcutis have been cured by early surgical excision.
In a report published in JAMA Pediatrics, 37.5% of all fatal pediatric opioid poisonings between 1999 and 2021 were related to fentanyl; most of the deaths were among adolescents (89.6%) (15–19 years) and children aged 0 to 4 years (6.6%). According to the UNODC, "the opioid crisis in North America is unabated, fueled by an unprecedented number of overdose deaths."
=== Stress response === Various cellular stress stimuli have been associated with changes in O-GlcNAc. Treatment with hydrogen peroxide, cobalt(II) chloride, UVB light, ethanol, sodium chloride, heat shock, and sodium arsenite, all result in elevated O-GlcNAc. Knockout of OGT sensitizes cells to thermal stress. Elevated O-GlcNAc has been associated with expression of Hsp40 and Hsp70.
=== Brand names === Numorphan (suppository and injectable solution) Opana ER (extended-release tablet): June 2017 FDA removal request due to rates of IV abuse. Opana IR (immediate-release tablet) O-Morphon in Bangladesh by Ziska pharmaceutical ltd. The brand name Numorphan is derived by analogy to the Nucodan name for an oxycodone product (or vice versa) as well as Paramorphan/Paramorfan for dihydromorphine and Paracodin (dihydrocodeine). The only commercially available salt of oxymorphone in most of the world at this time is the hydrochloride, which has a free base conversion ratio of 0.891, and oxymorphone hydrochloride monohydrate has a factor of 0.85. Generic pill markings are ATV10/APO; HK10 (10 mgs) oblong white and ATV20/APO; HK20 (20 mgs) oblong white.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.